Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 25;41(11):252.
doi: 10.1007/s12032-024-02504-4.

Personalized treatment approach for HER2-positive metastatic breast cancer

Prashant Pandey  1   2 , Rishabh Chaudhary  2 , Devika Tripathi  3 , Kousalya Lavudi  4   5 , Kamal Dua  6 , Michael Weinfeld  7 , Afsaneh Lavasanifar  1   8 , P S Rajinikanth  9
Affiliations
Review

Personalized treatment approach for HER2-positive metastatic breast cancer

Prashant Pandey et al. Med Oncol. .

Abstract

Breast cancer (BC) is a leading global concern for women, with 30% being HER2-positive cases linked to poorer outcomes. Targeted therapies like trastuzumab deruxtecan (T-DXd), trastuzumab, pertuzumab, and T-DM1 have revolutionized HER2-positive metastatic breast cancer (MBC) treatment. Although these therapies have improved MBC management and patient outcomes, resistance can develop, reducing effectiveness. Personalized strategies based on tumor characteristics offer hope for better responses and longer outcomes. This review outlines insights into MBC patients responding well to anti-HER2 treatments, even across multiple treatment regimen. Recent immunotherapy, locoregional therapy, and liquid biopsy breakthroughs are covered, suggesting ways to increase long-term responders. Personalized approaches have boosted HER2-positive MBC outcomes, and ongoing research is crucial to uncover new treatments and biomarkers, potentially elevating long-term response rates and prognoses. This may aid in providing new direction to breast cancer clinics.

Keywords: Anti-HER2; Breast cancer; HER2; Immunotherapy; Liquid biopsy; Locoregional.

PubMed Disclaimer

References

    1. Yu Y, et al. Advances in antibody-drug conjugates in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2022;14:417–32. - PubMed
    1. Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri VJEO. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open. 2022. https://doi.org/10.1016/j.esmoop.2022.100409 . - DOI - PubMed - PMC
    1. Deepak P, et al. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. J Drug Deliv Sci Technol. 2020;59: 101837.
    1. Gradishar WJ, et al. "NCCN Guidelines® insights: breast cancer, version 4.2021. J Natl Compr Canc Netw. 2021;19(5):484–93. - PubMed
    1. Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth PJDDT. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discovery Today. 2022;27:2526. - PubMed

MeSH terms

LinkOut - more resources